Adjuvant Capital — 2024 Investments
2 investments dated 2024 · listed companies and verified rows first · show all
LimmaTech develops vaccine technologies to address antimicrobial resistance by creating vaccines against pathogens that have become resistant to antibiotics.
AI & Machine LearningBiotechHealthtech
Co-investorsAndera PartnersTenmile
Memo Therapeutics develops therapeutic antibodies targeting viral infections to improve treatment outcomes for patients with conditions like BKPyV infection in kidney transplant recipients and oncological viral diseases.
BiotechMedical DevicesZurich, CH
Co-investorsKurma PartnersPureos BioventuresYsios CapitalFresenius Medical Care VenturesVerve Venturesredalpine
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.